🇺🇸 FDA
Pipeline program

Etelcalcetide

20150238

Phase 3 small_molecule completed

Quick answer

Etelcalcetide for Secondary Hyperparathyroidism is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen
Indication
Secondary Hyperparathyroidism
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials